Clinical Characteristics and Treatment Outcomes in Anti-CD20-treated Multiple Sclerosis Patients Who Switch to Natalizumab: A Komodo Health Sentinel Database Study (P8-1.016)
To determine the clinical characteristics of patients with multiple sclerosis (MS) who switch from B-cell depleting therapies (anti-CD20s) to natalizumab (NTZ; TYSABRI®); to estimate the annualized relapse rate (ARR), time to first relapse, and MS healthcare resource utilization (HRU) and healthcare costs (HCC).
Authors
- Jonathan Calkwood
- Dennis D. Long
- Thomas Shoemaker (ORCID: https://orcid.org/0000-0002-1085-6860)
- Yang Mao‐Draayer (ORCID: https://orcid.org/0000-0001-6248-3480)
- Claire Riley (ORCID: https://orcid.org/0000-0002-2133-9607)
- Nicholas Belviso
- Lana Zhovtis Ryerson (ORCID: https://orcid.org/0000-0003-1868-3893)
- Danette Rutledge
- Jeffrey English
- Sarah England
- Harry Lay
Institutions
- Rush University Medical Center (US)
- Biogen (United States) (US)
- Columbia University Irving Medical Center (US)
- Oklahoma Medical Research Foundation (US)
- Raleigh Neurology Associates (US)
- Neuroscience Institute (IT)
- Multiple Sclerosis Center of Atlanta (US)
- Jersey Shore University Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211921
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00